Greg Pyszczymuka
Corporate Officer/Principal chez AYTU BIOPHARMA, INC.
Fortune : 64 661 $ au 30/04/2024
Postes actifs de Greg Pyszczymuka
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| AYTU BIOPHARMA, INC. | Corporate Officer/Principal | - | - |
| NEOS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2018 | - |
Historique de carrière de Greg Pyszczymuka
Formation de Greg Pyszczymuka
| Rutgers State University of New Jersey | Undergraduate Degree |
| Argosy University | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AYTU BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
- Bourse
- Insiders
- Greg Pyszczymuka
- Expérience